Physician profile
Brandon Cometti
NPI 1265792022
$3,355.08
in general payments reported to CMS, 2019-2025
19 companies · $833 in 2025
The $833 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.95 · 2020: $99.99 · 2021: $15.39 · 2022: $300 · 2023: $992 · 2024: $1,044 · 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,520 · Education: $349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,520.44 |
| Education | $349.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $852.23 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $759.72 | 2021-2025 | Rinvoq, Skyrizi |
| Regeneron Healthcare Solutions, INC. | $278.37 | 2023-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $277.29 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $238.64 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $202.32 | 2022-2024 | Opzelura |
| Amgen INC. | $185.54 | 2022-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $104.17 | 2024-2025 | Nemluvio |
| Merz North America, INC. | $96.69 | 2023-2024 | Xeomin |
| Genzyme Corporation | $83.87 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $52.55 | 2023-2024 | |
| Pfizer INC. | $41.39 | 2022-2023 | |
| Sandoz INC. | $38.73 | 2023-2024 | Hyrimoz |
| Organon LLC | $32.71 | 2023 | Hadlima |
| Krystal Biotech INC | $30.59 | 2024 | Vyjuvek |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $26.82 | 2024 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.20 | 2023 | Cyltezo |
| Dermavant Sciences, INC. | $15.61 | 2022 | |
| Fresenius Kabi USA, LLC | $13.64 | 2024 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Cometti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.